Domain Therapeutics

What is Domain Therapeutics?

Domain Therapeutics is a biopharmaceutical company with headquarters in Strasbourg, France, and additional operations in Montreal, Canada. The firm specializes in the discovery and early development of small molecules targeting G Protein-Coupled Receptors (GPCRs), which are considered one of the top classes of drug targets.

They apply their proprietary technology platform, DTect-All, to identify orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), that represent a unique source of compounds otherwise undetected by standard technologies. DTect-All is competent in addressing challenging GPCRs, such as orphan and peptidic GPCRs. Their focus extends to the development of treatments targeting GPCR-mediated immunosuppression with the aim of achieving significant clinical outcomes in the battle against cancer.

They adopt a holistic and patient-centered approach, recognizing the complexity of cancer and the limitations of current treatment methods. They are committed to precision research, delivering differentiated and effective GPCR-targeting cancer immunotherapies tailored to maximize patient benefits.

This involves understanding GPCRs' role in modulating the immune system, tumor biology, and the tumor microenvironment.

They avoid one-size-fits-all solutions by identifying the correct tumor types, patient sub-populations, and combination treatments, ensuring optimal positioning of their immunotherapies to enhance the efficacy of cancer treatment. Their innovative approach includes the development of a robust and clinically relevant biomarker strategy at the early stages of drug development to reverse GPCR-mediated immunosuppression in immuno-oncology.

This expertise allows them to bring differentiated cancer immunotherapies to the clinic and improve patient outcomes. Domain Therapeutics' growing portfolio includes various phases of drug candidates, from discovery to Phase I clinical trials, and they are actively involved in partnerships to strengthen their research and development efforts.

Their investment minima and maxima align at $9,000,000, demonstrating their strategic focus on early-stage investments.